Cargando…
Difamilast for the treatment of atopic dermatitis
Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease. The pathogenesis of AD is complex and still not fully understood. Despite recent therapeutic developments, the current therapeutic arsenal of AD remains limited and is associated with long-term efficacy and safety issues...
Autores principales: | Freitas, Egídio, Torres, Tiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328024/ https://www.ncbi.nlm.nih.gov/pubmed/37389929 http://dx.doi.org/10.1177/03000605231169445 |
Ejemplares similares
-
Selective IL-13 inhibitors for the treatment of atopic dermatitis
por: Gonçalves, Francisca, et al.
Publicado: (2021) -
Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study
por: Saeki, Hidehisa, et al.
Publicado: (2022) -
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double‐blind, vehicle‐controlled trial
por: Saeki, H., et al.
Publicado: (2021) -
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023) -
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)